Clinical Study
Eye (2006) 20, 13–17. doi:10.1038/sj.eye.6701803; published online 18 February 2005
Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion
Authors have no financial or proprietary interest in any products used in this study.
A Özkiris1, C Evereklioglu1, K Erkilic2 and H Dogan2
- 1Assistant Professor of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Turkey
- 2Professor of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Turkey
Correspondence: A Özkiris, Y
ldrm Beyazt mah. Mustafa Simsek, Cad. Kardelen Apt. No: 121/16, TR-38030 Melikgazi, Kayseri, Turkey. Tel: +90 532 522 3119; Fax: +90 352 437 4912; E-mail: aozkiris@erciyes.edu.tr
Received 5 April 2004; Accepted 27 July 2004; Published online 18 February 2005.
Abstract
Background
To evaluate the efficacy of intravitreal triamcinolone acetonide injection on persistent macular oedema in branch retinal vein occlusion that fails to respond to previous laser photocoagulation.
Material and methods
A total of 19 eyes of 19 patients with persistent macular oedema due to branch retinal vein occlusion were treated with 8 mg/0.2 ml of intravitreal triamcinolone acetonide injection. The main outcome measures included best-corrected visual acuity, intraocular pressure, and macular oedema map values of Heidelberg Retinal Tomograph II (HRT II) before and after intravitreal triamcinolone injection.
Results
The mean follow-up time was 6.2
1.0 months. The mean baseline best-corrected logarithm of minimal angle of resolution (LogMAR) value for visual acuities of the patients before intravitreal triamcinolone injection was 1.010.16. After treatment, it was 0.550.22 at the 1-month, 0.560.22 at 3-month, and 0.620.22 at the last visits and the differences were statistically significant when compared with baseline values (for each, P<0.001). The mean oedema map values on HRT II significantly decreased by 28.5% at 1-month, 23.8% at 3-month, and 23.8% at the last visit when compared with preinjection values (for each, P<0.001). Intraocular pressure elevation exceeding 21 mmHg was observed in 26.3% of eyes at 1-month, 15.7% at 3-month, and 5.2% at the last visit, but was controlled with topical antiglaucomatous medications in all eyes.
Conclusion
Intravitreal triamcinolone acetonide application is a promising approach in the treatment of persistent macular oedema due to branch retinal vein occlusion nonrespondent to laser photocoagulation.
Keywords:
intravitreal triamcinolone acetonide, persistent macular oedema, branch retinal vein occlusion
